Osiris Provides An Update On A Clinical Review By Blue Cross Blue Shield Association

COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that the Blue Cross Blue Shield Association has provided a positive review on Grafix® usage for individuals with diabetic lower-extremity ulcers.

Back to news